Related references
Note: Only part of the references are listed.Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
Melania Gaggini et al.
HEPATOLOGY (2018)
Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
Varman T. Samuel et al.
CELL METABOLISM (2018)
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis
Zobair M. Younossi et al.
HEPATOLOGY (2018)
Pharmacotherapy for NASH: Current and emerging
Monica A. Konerman et al.
JOURNAL OF HEPATOLOGY (2018)
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Yaron Rotman et al.
GUT (2017)
NAFLD and diabetes mellitus
Herbert Tilg et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Targeting the Mitochondrial Pyruvate Carrier Attenuates Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis
Kyle S. McCommis et al.
HEPATOLOGY (2017)
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis A Meta-analysis
Giovanni Musso et al.
JAMA INTERNAL MEDICINE (2017)
The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity
Adam J. Rauckhorst et al.
MOLECULAR METABOLISM (2017)
Treating Fatty Liver Disease by Modulating Mitochondrial Pyruvate Metabolism
Jerry R. Colca et al.
HEPATOLOGY COMMUNICATIONS (2017)
Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level
Silvia Sookoian et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2016)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial
Kenneth Cusi et al.
ANNALS OF INTERNAL MEDICINE (2016)
The mitochondrial pyruvate carrier in health and disease: To carry or not to carry?
Tom Bender et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
The Globalization of Nonalcoholic Fatty Liver Disease: Prevalence and Impact on World Health
Mary Rinella et al.
HEPATOLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Molecular Pathogenesis of NASH
Alessandra Caligiuri et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9
Irma Garcia-Martinez et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Mitochondrial pyruvate transport: a historical perspective and future research directions
Kyle S. McCommis et al.
BIOCHEMICAL JOURNAL (2015)
The TZD insulin sensitizer clue provides a new route into diabetes drug discovery
Jerry R. Colca
EXPERT OPINION ON DRUG DISCOVERY (2015)
An Insulin-Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss
Tomohiro Fukunaga et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Current efforts and trends in the treatment of NASH
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2015)
Mitochondrial target of thiazolidinediones
J. R. Colca et al.
DIABETES OBESITY & METABOLISM (2014)
Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases
Jerry R. Colca et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Glutamine Oxidation Maintains the TCA Cycle and Cell Survival during Impaired Mitochondrial Pyruvate Transport
Chendong Yang et al.
MOLECULAR CELL (2014)
Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
J. R. Colca et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)-Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins
Jerry R. Colca et al.
PLOS ONE (2013)
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Ajit S. Divakaruni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
Carolina Ortiz-Lopez et al.
DIABETES CARE (2012)
Insulin Resistance and Metabolic Derangements in Obese Mice Are Ameliorated by a Novel Peroxisome Proliferator-activated Receptor γ-sparing Thiazolidinedione
Zhouji Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Identification and Functional Expression of the Mitochondrial Pyruvate Carrier
Sebastien Herzig et al.
SCIENCE (2012)
Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings
Elizabeth M. Brunt et al.
HEPATOLOGY (2011)
A role for mitochondria in NLRP3 inflammasome activation
Rongbin Zhou et al.
NATURE (2011)
Share Paper
